Publication: Scleral necrosis after plaque radiotherapy of uveal melanoma: A case-control study
Issued Date
2013-05-01
Resource Type
ISSN
15494713
01616420
01616420
Other identifier(s)
2-s2.0-84877745683
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Ophthalmology. Vol.120, No.5 (2013), 1004-1011
Suggested Citation
Swathi Kaliki, Carol L. Shields, Duangnate Rojanaporn, Josep Badal, Laxmi Devisetty, Jacqueline Emrich, Lydia Komarnicky, Jerry A. Shields Scleral necrosis after plaque radiotherapy of uveal melanoma: A case-control study. Ophthalmology. Vol.120, No.5 (2013), 1004-1011. doi:10.1016/j.ophtha.2012.10.021 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/32375
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Scleral necrosis after plaque radiotherapy of uveal melanoma: A case-control study
Other Contributor(s)
Abstract
Purpose: To identify risk factors and outcome of scleral necrosis after plaque radiotherapy of uveal melanoma. Design: Case-control study. Participants: A total of 73 cases with scleral necrosis and 73 controls without necrosis after plaque radiotherapy. Controls were matched for anteroposterior tumor epicenter and follow-up duration. Intervention: Plaque radiotherapy with iodine-125, cobalt-60, iridium-192, or ruthenium-106. Main Outcome Measures: Scleral necrosis. Results: Of 5057 patients treated with plaque radiotherapy for uveal melanoma, 73 (1%) developed radiotherapy-induced scleral necrosis. Scleral necrosis occurred in <1% of patients (3/1140) when plaque radiotherapy was used for tumors <3 mm in thickness, 1% of patients (33/3155) with 3- to 8-mm tumor thickness, and 5% of patients (37/762) with >8-mm-thick tumors. On the basis of tumor location, scleral necrosis was detected after plaque radiotherapy of iris melanoma in 0% of patients (0/91), ciliary body melanoma in 29% of patients (67/235), and choroid melanoma in <1% of patients (6/4731). The mean time interval between plaque radiotherapy and scleral necrosis was 32 months (median, 23 months; range, 4-126 months). The mean basal dimension of scleral necrosis was 4 mm (median, 3 mm; range, 1-15 mm), equivalent to 29% of mean tumor base (median, 24%; range, 6%-100%) and 22% of mean plaque size (median, 19%; range, 5%-75%). Multivariate analysis of factors that predicted clinically evident scleral necrosis included ciliary body (P = 0.0001) and pars plana to ora serrata (P < 0.0001) locations of anterior tumor margin, tumor thickness ≥6 mm (P = 0.0001), and radiation dose ≥400 Gy to the outer sclera (P = 0.0455). Scleral necrosis remained stable in 48% of patients (35/73), increased in size/severity in 48% of patients (35/73), or progressed to scleral perforation in 4% of patients (3/73) over a mean follow-up of 79 months (median, 54 months; range, 5-351 months). Treatment of scleral necrosis included observation in 81% of patients (59/73), scleral patch graft in 14% of patients (10/73), and enucleation in 5% of patients (4/73). Conclusions: Scleral necrosis after plaque radiotherapy of uveal melanoma was detected in 1% of cases. Factors predictive of scleral necrosis included increasing tumor thickness, ciliary body and peripheral choroidal location, and higher radiation dose to sclera. Most patients (81%) did not require treatment, and 4% evolved to full-thickness perforation. © 2013 American Academy of Ophthalmology.